| __timestamp | Halozyme Therapeutics, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79696000 | 45967000 |
| Thursday, January 1, 2015 | 93236000 | 114737000 |
| Friday, January 1, 2016 | 150842000 | 183204000 |
| Sunday, January 1, 2017 | 150643000 | 231644000 |
| Monday, January 1, 2018 | 150252000 | 293998000 |
| Tuesday, January 1, 2019 | 140804000 | 357355000 |
| Wednesday, January 1, 2020 | 34236000 | 412084000 |
| Friday, January 1, 2021 | 35672000 | 497153000 |
| Saturday, January 1, 2022 | 66607000 | 705789000 |
| Sunday, January 1, 2023 | 76363000 | 648449000 |
| Monday, January 1, 2024 | 79048000 |
Igniting the spark of knowledge
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Halozyme Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Ultragenyx consistently outspent Halozyme, with its R&D expenses peaking at approximately 705% higher than Halozyme's lowest expenditure year. Notably, in 2022, Ultragenyx's R&D spending reached its zenith, marking a 54% increase from its 2014 levels. Meanwhile, Halozyme's R&D investment showed a more fluctuating trend, with a significant dip in 2020, followed by a gradual recovery. This disparity highlights Ultragenyx's aggressive pursuit of innovation, while Halozyme adopts a more conservative approach. As the biotech landscape continues to shift, these spending patterns may offer insights into each company's strategic priorities and future growth potential.
Eli Lilly and Company or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for GSK plc and Ultragenyx Pharmaceutical Inc.
Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc.
Comparing Innovation Spending: United Therapeutics Corporation and Ultragenyx Pharmaceutical Inc.
Research and Development Investment: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and MannKind Corporation
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Viridian Therapeutics, Inc.